NEUROLOGICAL SCIENCES, vol.44, no.9, pp.3335-3339, 2023 (SCI-Expanded)
As treatment options for cancer and autoimmune diseases
are developing each day, iatrogenic central demyelination
case reports are increasing in number. Tumor necrosis factoralpha inhibitors and immune-checkpoint inhibitors are the
most frequently reported agents in iatrogenic central nervous
system demyelination cases [1]. Recently, there have been
reports on iatrogenic peripheral and central demyelination
associated with tyrosine kinase inhibitors. Nilotinib is a second generation tyrosine kinase inhibitor targeting the Bcr-abl
translocation, and used in chronic myeloid leukemia (CML)
[2]. A possible central demyelination associated with the use
of nilotinib will be presented in this case report.